ProfoundBio is an industry leader in Antibody-Drug Conjugates (ADC) technology and its applications in the treatment of cancer. We develop next generation novel proprietary drug linker technology harnessing the targeting power of antibodies to deliver small molecule drugs to the for improved efficacy and tolerability.
Antibody-drug conjugates precisely and specifically deliver a potent cytotoxin to tumor cells that express the target antigen to kill those tumor cells. 
Normal cells have minimal to no expression of target antigen and are hence spared, resulting in a widened therapeutic window.